{
  "trial_id": "NCT04109391",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, hormone receptor status, surgical resection status, neoadjuvant treatment completion status, pregnancy test results, use of contraception, presence of breast cancer metastases, presence of residual disease post-operatively, medical history, lactation status, planned adjuvant therapy, compliance with study protocol.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Hormone Receptor Status",
          "hormone receptor status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Tumor Stage",
        "ECOG"
      ],
      "remaining_candidate_features": [
        "surgical resection status",
        "neoadjuvant treatment completion status",
        "pregnancy test results",
        "use of contraception",
        "presence of breast cancer metastases",
        "presence of residual disease post-operatively",
        "medical history",
        "lactation status",
        "planned adjuvant therapy",
        "compliance with study protocol."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, Hormone Receptor Status, Surgical Resection Status, Prior Neoadjuvant Treatment, Adjuvant Radiation Therapy, Adjuvant Hormonal Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Hormone Receptor Status",
          "Hormone Receptor Status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Tumor Stage",
        "ECOG"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Surgical Resection Status",
        "Prior Neoadjuvant Treatment",
        "Adjuvant Radiation Therapy",
        "Adjuvant Hormonal Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Region of Enrollment, Menopausal Status, Hormone Receptor Status, HER2 Status, Tumor Size, Nodal Status, Histological Grade, Ki-67, Surgical Resection Margin Status, Adjuvant Radiation Therapy, Adjuvant Hormonal Therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Hormone Receptor Status",
          "Hormone Receptor Status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Tumor Stage",
        "ECOG"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Menopausal Status",
        "HER2 Status",
        "Tumor Size",
        "Nodal Status",
        "Histological Grade",
        "Ki-67",
        "Surgical Resection Margin Status",
        "Adjuvant Radiation Therapy",
        "Adjuvant Hormonal Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), performance status, tumor stage, hormone receptor status, menopausal status, prior chemotherapy, prior radiation therapy, surgical procedure, time from surgery to adjuvant treatment, left ventricular ejection fraction (LVEF) at baseline, prior trastuzumab exposure, number of cycles of trastuzumab received in the neoadjuvant study.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Hormone Receptor Status",
          "hormone receptor status"
        ],
        [
          "Tumor Stage",
          "tumor stage"
        ],
        [
          "ECOG",
          "performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "menopausal status",
        "prior chemotherapy",
        "prior radiation therapy",
        "surgical procedure",
        "time from surgery to adjuvant treatment",
        "left ventricular ejection fraction (LVEF) at baseline",
        "prior trastuzumab exposure",
        "number of cycles of trastuzumab received in the neoadjuvant study."
      ]
    }
  }
}